AC Immune is a Swiss clinical-stage biopharmaceutical company that spent 2025 in retreat. Revenue collapsed to $4.3 million from $32.5 million a year earlier, the annual net loss widened to $83.9 million, and in September 2025 a strategic review forced a restructuring that cut headcount and carved out a leaner pipeline. The first half of 2026 is the first window since that reset in which the new shape of the company is actually visible - and the two halves of the story have never been clearer. A day after the H1 numbers hit the tape, the FDA granted Fast Track designation and cleared the Investigational New Drug application for ACI-7104, the wholly owned anti-alpha-synuclein immunotherapy for early Parkinson's disease, opening the door to U.S. enrollment in the ongoing VacSYn Phase 2 trial.
What changed in H1 2026 is a genuine financial inflection, not just a smaller checkbook. Contract revenue surged to $20.4 million (CHF 16.2 million) from $2.6 million (CHF 2.3 million) a year ago, while research and development spending fell to $27.9 million from $37.5 million after the reorganization. The net loss narrowed to $16.3 million (CHF 12.9 million) from $46.1 million (CHF 40.2 million), a swing driven by both higher collaboration income and a roughly one-third cut in R&D costs. Liquidity stood at $92 million (CHF 75.4 million) as of June 30, and management states those resources fund operations through the fourth quarter of 2027 with no additional milestone payments assumed.
The central tension is whether this is now a catalyst-driven story built on wholly owned programs or a partner-optionality story whose value still rests on external decisions. The stock trades at $2.54, near its 52-week low of $2.03, despite holding roughly $0.93 per share in cash and short-term investments - the market is paying a modest premium for a pipeline. The deciding hinge is the fourth quarter, when the week-100 Part 1 results from the VacSYn trial in early Parkinson's disease are expected. Positive immunogenicity and biomarker data there would validate the Fast Track decision and the whole thesis that the reset freed capital for high-conviction science; a null or safety-flagged read would likely press the shares back toward their cash value. Everything else in the portfolio - the Takeda and Lilly collaborations worth more than $4.5 billion in potential milestones, the NLRP3 small molecule, the TDP-43 imaging tracer - is secondary to that one late-2026 readout.